Kamal Pandey

Songnam, Republic of Korea

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Radiation synergizes with BET inhibition to stimulate durable, systemic anti-tumor immunity in murine cancer models.

Radiation synergizes with BET inhibition to stimulate durable, systemic anti-tumor immunity in murine cancer models.

Journal: bioRxiv : the preprint server for biology

Published: February 27, 2026

The non-kinase function of CDK6 is a key driver of acquired resistance to CDK4/6 inhibitors in Estrogen Receptor-positive breast cancer.

The non-kinase function of CDK6 is a key driver of acquired resistance to CDK4/6 inhibitors in Estrogen Receptor-positive breast cancer.

Journal: bioRxiv : the preprint server for biology

Published: November 26, 2025

Intratumoral Injection of Allogeneic NK Cell With Chemotherapy in a Triple-negative Breast Cancer Preclinical Model.

Intratumoral Injection of Allogeneic NK Cell With Chemotherapy in a Triple-negative Breast Cancer Preclinical Model.

Journal: Anticancer research

Published: April 21, 2025

Preclinical Platform Using a Triple-negative Breast Cancer Syngeneic Murine Model to Evaluate Immune Checkpoint Inhibitors.

Preclinical Platform Using a Triple-negative Breast Cancer Syngeneic Murine Model to Evaluate Immune Checkpoint Inhibitors.

Journal: Anticancer research

Published: October 25, 2022

Towards precision radiation oncology: endocrine therapy response as a biomarker for personalization of breast radiotherapy.

Towards precision radiation oncology: endocrine therapy response as a biomarker for personalization of breast radiotherapy.

Journal: NPJ precision oncology

Published: July 10, 2022

Combination of Abemaciclib following Eribulin Overcomes Palbociclib-Resistant Breast Cancer by Inhibiting the G2/M Cell Cycle Phase.

Combination of Abemaciclib following Eribulin Overcomes Palbociclib-Resistant Breast Cancer by Inhibiting the G2/M Cell Cycle Phase.

Journal: Cancers

Published: October 25, 2021

Deregulated Immune Pathway Associated with Palbociclib Resistance in Preclinical Breast Cancer Models: Integrative Genomics and Transcriptomics.

Deregulated Immune Pathway Associated with Palbociclib Resistance in Preclinical Breast Cancer Models: Integrative Genomics and Transcriptomics.

Journal: Genes

Published: December 08, 2020

Synergism of AZD6738, an ATR Inhibitor, in Combination with Belotecan, a Camptothecin Analogue, in Chemotherapy-Resistant Ovarian Cancer.

Synergism of AZD6738, an ATR Inhibitor, in Combination with Belotecan, a Camptothecin Analogue, in Chemotherapy-Resistant Ovarian Cancer.

Journal: International journal of molecular sciences

Published: December 08, 2020

Preclinical platform for long-term evaluation of immuno-oncology drugs using hCD34+ humanized mouse model.

Preclinical platform for long-term evaluation of immuno-oncology drugs using hCD34+ humanized mouse model.

Journal: Journal for immunotherapy of cancer

Published: November 09, 2020

Combined CDK2 and CDK4/6 Inhibition Overcomes Palbociclib Resistance in Breast Cancer by Enhancing Senescence.

Combined CDK2 and CDK4/6 Inhibition Overcomes Palbociclib Resistance in Breast Cancer by Enhancing Senescence.

Journal: Cancers

Published: November 05, 2020

Molecular mechanisms of resistance to CDK4/6 inhibitors in breast cancer: A review.

Molecular mechanisms of resistance to CDK4/6 inhibitors in breast cancer: A review.

Journal: International journal of cancer

Published: September 01, 2018

Showing 1-11 of 11

Last Updated: 09/26/2026